Treatment of mucositis with immunoglobulin

Patent metadata

Field	Value
Publication number	US-9546209-B2
Application number	US-201314380457-A
Country	US
Kind code	B2
Filing date	Mar 8, 2013
Priority date	Mar 9, 2012
Publication date	Jan 17, 2017
Grant date	Jan 17, 2017

Abstract

The invention relates to compositions comprising immunoglobulin for use in the treatment of mucositis by topical application. In particular, the invention relates to compositions comprising J chain-containing IgA and secretory component for the treatment of mucositis.

First claim

The invention claimed is:

1. A method for the prevention or treatment of mucositis of the alimentary tract comprising:
administering topically to a human subject an effective amount of a composition comprising an effective amount of immunoglobulin derived from pooled human plasma to prevent or treat mucositis of the alimentary tract,
with the proviso that the plasma derived immunoglobulin is not a pure anti-TNF antibody or immunoglobulin enriched for anti-TNF or purified from a human or animal donor immunized with TNF-α.

2. The method of claim 1 , wherein the mucositis of the alimentary tract is oral mucositis.

3. The method of claim 2 , wherein the patient is undergoing chemotherapy and the patient becomes neutropenic.

4. The method of claim 1 , wherein the immunoglobulin comprises IgA or IgM or a combination thereof.

5. The method of claim 3 , wherein the immunoglobulin comprises J chain-containing IgA.

6. The method of claim 1 , wherein the composition also comprises secretory component.

7. The method of claim 6 , wherein the secretory component is recombinant secretory component.

8. The method of claim 1 , wherein the composition comprises J-chain containing IgA combined with a protein that is secretory component or a functional variant thereof.

9. The method of claim 1 , wherein the composition comprises J-chain containing IgA combined with a protein that is secretory component or a functional variant thereof in combination with another immunoglobulin.

10. The method of claim 1 , wherein the composition is formulated to provide a long contact time with the mucosal area affected or at risk of becoming affected by mucositis.

11. The method of claim 10 , wherein the composition formulation is selected from a cream, a gel, a syrup, a jelly, a solid form which dissolved near the affected mucosa, or combinations thereof.

12. The method of claim 1 , wherein the topical application to the mucosa promotes mucosal wound healing.

13. The method of claim 1 , wherein the topical application to the mucosa exerts an anti-inflammatory effect.

14. The method of claim 13 , wherein the anti-inflammatory effect is
(a) inhibition of pro-inflammatory cytokine expression; and/or
(b) stimulation of the expression of anti-inflammatory cytokines.

15. The method of claim 1 , wherein the subject is a subject at risk of developing mucositis of the alimentary tract.

16. The method of claim 15 , wherein the subject at risk is a cancer patient who developed mucositis as a result of a previous chemotherapy and/or radiotherapy treatment.

17. The method of claim 15 , wherein the administration of the composition commences when the patient's neutrophil count starts declining.

18. The method of claim 17 , wherein the treatment is maintained for the period where the patient's neutrophil count is below normal.

19. The method of claim 1 , wherein the composition is administered to the subject up to 6 times per day.

20. The method of claim 1 , wherein the composition comprises an additional effective agent for the treatment of mucositis, or wherein the patient is also using another agent.

21. The method of claim 15 , wherein the subject at risk is a cancer patient undergoing chemotherapy and/or radiotherapy.

22. The method of claim 20 , wherein the another agent is an antiseptic mouthwash.

23. The method of claim 1 , wherein said composition is applied topically in the mouth of a patient having oral mucositis to improve symptoms of said oral mucositis.

24. The method of claim 1 , wherein the subject is a cancer patient about to undergo chemotherapy and/or radiotherapy.

25. The method of claim 1 , wherein active ingredient(s) in the composition consist essentially of components derived from pooled human plasma including said immunoglobulin.

26. The method of claim 1 , wherein active ingredient(s) in the composition consists essentially of said immunoglobulin derived from pooled human plasma.

27. The method of claim 24 , which comprises the further step of subjecting the cancer patient to chemotherapy and/or after administration of a composition comprising an effective amount of immunoglobulin derived from pooled human plasma.

28. A method for the treatment of oral mucositis comprising:
oral/buccal administration to a human subject of an effective amount of a composition comprising an effective amount of immunoglobulin derived from pooled human plasma to treat oral mucositis, with the proviso that the plasma derived immunoglobulin is not a pure anti-TNF antibody or immunoglobulin enriched for anti-TNF or purified from a human or animal donor immunized with TNF-α.

Assignees

• Csl Behring Ag
• Univ Bern

Inventors

• Aebi Christoph
• Lueer Sonja Christina
• Schaub Alexander
• Miescher Sylvia
• Zuercher Adrian
• Vonarburg Cédric Pierre

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/10

  Antimycotics · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• C07K16/1203

  Gram-negative bacteria · CPC title